In February 2021, Azurity Pharmaceuticals acquired three drugs from Eton Pharmaceutical’s neurology portfolio. To date, two of those three drugs have now been approved by the FDA. The most recent is Zonisade, the first authorized liquid medication to treat epilepsy in patients 16 years and older. The approval was delayed due to COVID travel restrictions which prevented a manufacturing site inspection in 2021.
Click here to read the entire article.